Seize the engine: Emerging cell cycle targets in breast cancer
Clinical and Translational Medicine · 2024-01 · 14 (1)
DOI: 10.1002/ctm2.1544 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 24.01.2024. Verfasst von Jesús Fuentes-Antrás und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, University of Toront…. Hauptthemen laut MEDLINE: Aurora Kinase A, Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 268 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Princess Margaret Cancer Foundation.
Abstract (Originalsprache)
Breast cancer arises from a series of molecular alterations that disrupt cell cycle checkpoints, leading to aberrant cell proliferation and genomic instability. Targeted pharmacological inhibition of cell cycle regulators has long been considered a promising anti‐cancer strategy. Initial attempts to drug critical cell cycle drivers were hampered by poor selectivity, modest efficacy and haematological toxicity. Advances in our understanding of the molecular basis of cell cycle disruption and the mechanisms of resistance to CDK4/6 inhibitors have reignited interest in blocking specific components of the cell cycle machinery, such as CDK2, CDK4, CDK7, PLK4, WEE1, PKMYT1, AURKA and TTK. These targets play critical roles in regulating quiescence, DNA replication and chromosome segregation. Extensive preclinical data support their potential to overcome CDK4/6 inhibitor resistance, induce synthetic lethality or sensitise tumours to immune checkpoint inhibitors. This review provides a biological and drug development perspective on emerging cell cycle targets and novel inhibitors, many of which exhibit favourable safety profiles and promising activity in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
- NEXT Oncology, Hospital Universitario QuironSalud Madrid, Madrid, Spain.
ORCID-Profile: Jesús Fuentes-Antrás
Förderung
- NCI NIH HHS
- Princess Margaret Cancer Foundation
Zitieren
APA
Fuentes-Antrás, J., Bedard, P. L., & Cescon, D. W. (2024). Seize the engine: Emerging cell cycle targets in breast cancer. Clinical and Translational Medicine, 14(1). https://doi.org/10.1002/ctm2.1544
Vancouver
Fuentes-Antrás J, Bedard PL, Cescon DW. Seize the engine: Emerging cell cycle targets in breast cancer. Clinical and Translational Medicine. 2024;14(1). doi:10.1002/ctm2.1544
BibTeX
@article{FuentesAntrs2024,
author = {Fuentes-Antrás, Jesús and Bedard, Philippe L and Cescon, David W},
title = {Seize the engine: Emerging cell cycle targets in breast cancer},
journal = {Clinical and Translational Medicine},
year = {2024},
volume = {14},
number = {1},
doi = {10.1002/ctm2.1544}
}
EUVIMED